TY - JOUR
T1 - Mutations of the estrogen receptor in endometrial carcinoma
T2 - Evidence of an association with high tumor grade
AU - Assikis, Vasilios J.
AU - Bilimoria, Malcolm M.
AU - Muenzner, Henry D.
AU - Lurain, John R.
AU - Jordan, V. Craig
N1 - Funding Information:
The authors are extremely grateful to the Lynn Sage Breast Cancer Research Foundation and the Eileen M. Arder Fund for Endometrial Cancer Research for the support of this study.
PY - 1996/11
Y1 - 1996/11
N2 - The majority (60-70%) of endometrial cancers express estrogen receptor. Typically, estrogen-receptor-positive endometrial tumors are associated with a more favorable outcome. Despite this, there is often a discrepancy between estrogen receptor expression and clinical outcome of the disease. Although little is known about the exact role of the estrogen receptor in endometrial malignancies, in breast cancer, where such information is abundant, a number of mutations of the estrogen receptor have been identified. To investigate whether mutations of the estrogen receptor gene occur in endometrial cancers we performed single-stranded conformational polymorphism analysis (SSCP) on 35 human endometrial tumors. We detected four point mutations in three different patients. Interestingly, all the mutations were detected in patients who had aggressive endometrial tumors (grade 3). Although we found the incidence of mutations of the estrogen receptor to be low (8.5%) and thus unlikely to be associated with the majority of endometrial cancers, further investigation is needed to elucidate the role of aberrant estrogen receptor expression in the progression of endometrial malignancies.
AB - The majority (60-70%) of endometrial cancers express estrogen receptor. Typically, estrogen-receptor-positive endometrial tumors are associated with a more favorable outcome. Despite this, there is often a discrepancy between estrogen receptor expression and clinical outcome of the disease. Although little is known about the exact role of the estrogen receptor in endometrial malignancies, in breast cancer, where such information is abundant, a number of mutations of the estrogen receptor have been identified. To investigate whether mutations of the estrogen receptor gene occur in endometrial cancers we performed single-stranded conformational polymorphism analysis (SSCP) on 35 human endometrial tumors. We detected four point mutations in three different patients. Interestingly, all the mutations were detected in patients who had aggressive endometrial tumors (grade 3). Although we found the incidence of mutations of the estrogen receptor to be low (8.5%) and thus unlikely to be associated with the majority of endometrial cancers, further investigation is needed to elucidate the role of aberrant estrogen receptor expression in the progression of endometrial malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0030297871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030297871&partnerID=8YFLogxK
U2 - 10.1006/gyno.1996.0305
DO - 10.1006/gyno.1996.0305
M3 - Article
C2 - 8910626
AN - SCOPUS:0030297871
SN - 0090-8258
VL - 63
SP - 192
EP - 199
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -